The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Results for Maintenance Olaparib in BRCA-Mutated Platinum-Sensitive Ovarian Cancer

Michael Birrer, MD, PhD
Published Online: 12:28 AM, Sun June 4, 2017

Michael Birrer, MD, PhD, Director, University of Alabama Comprehensive Cancer Center, discusses adverse event results of the phase III SOLO2 trial, which explored maintenance olaparib (Lynparza) tablets in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.